Commentary|Articles|July 15, 2026

Expert Q&A: What the MMRV Vaccine Equity Data Mean for Pharmacists

Author(s)Eric J. Chow, MD, MS, MPH, Kennedy Ferruggia, Associate Editor

An expert discusses a JAMA study that shows who depends on the MMRV combination vaccine and how policy shifts may widen gaps—plus how pharmacists keep children on schedule.

As debate continues over the Advisory Committee on Immunization Practices' (ACIP) September 2025 vote to stop recommending the combined measles, mumps, rubella, and varicella (MMRV) vaccine for children younger than 4 years—a decision stayed by a US District Court ruling in AAP v Kennedy as of March 16, 2026—a new JAMA Network Open study is offering some of the first population-level evidence on who actually relies on the combination shot and what could be lost if it disappears from the recommended schedule.